Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-10-31 DOI:10.1016/j.ccell.2024.10.001

James W. Smithy, Michael A. Postow

引用次数: 0

Abstract

Combinatorial immunotherapy may improve the efficacy of neoadjuvant checkpoint inhibitors in locoregionally advanced melanoma. In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.

查看原文本刊更多论文

瘤体内维杜莫德联合 PD-1 阻断治疗局部晚期黑色素瘤

联合免疫疗法可提高新辅助检查点抑制剂在局部晚期黑色素瘤中的疗效。在本期《癌细胞》（Cancer Cell）杂志上，Davar及其同事报告了TLR9激动剂vidutolimod联合nivolumab的一项前景看好的新辅助治疗2期试验。分析表明，一种独特的骨髓表达特征与反应有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.